Antibiotics (May 2021)

Discovery of Pyrrolidine-2,3-diones as Novel Inhibitors of <em>P. aeruginosa</em> PBP3

  • Arancha López-Pérez,
  • Stefan Freischem,
  • Immanuel Grimm,
  • Oliver Weiergräber,
  • Andrew J. Dingley,
  • María Pascual López-Alberca,
  • Herbert Waldmann,
  • Waldemar Vollmer,
  • Kamal Kumar,
  • Cuong Vuong

DOI
https://doi.org/10.3390/antibiotics10050529
Journal volume & issue
Vol. 10, no. 5
p. 529

Abstract

Read online

The alarming threat of the spread of multidrug resistant bacteria currently leaves clinicians with very limited options to combat infections, especially those from Gram-negative bacteria. Hence, innovative strategies to deliver the next generation of antibacterials are urgently needed. Penicillin binding proteins (PBPs) are proven targets inhibited by β-lactam antibiotics. To discover novel, non-β-lactam inhibitors against PBP3 of Pseudomonas aeruginosa, we optimised a fluorescence assay based on a well-known thioester artificial substrate and performed a target screening using a focused protease-targeted library of 2455 compounds, which led to the identification of pyrrolidine-2,3-dione as a potential scaffold to inhibit the PBP3 target. Further chemical optimisation using a one-pot three-component reaction protocol delivered compounds with excellent target inhibition, initial antibacterial activities against P. aeruginosa and no apparent cytotoxicity. Our investigation revealed the key structural features; for instance, 3-hydroxyl group (R2) and a heteroaryl group (R1) appended to the N-pyrroldine-2,3-dione via methylene linker required for target inhibition. Overall, the discovery of the pyrrolidine-2,3-dione class of inhibitors of PBP3 brings opportunities to target multidrug-resistant bacterial strains and calls for further optimisation to improve antibacterial activity against P. aeruginosa.

Keywords